Completed NA INTERVENTIONAL NCT00002354

A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients

One Year Study in HIV-1 Seropositive, AZT-Experienced Patients to Evaluate the Safety and Efficacy of MK-639 Administered Concomitantly With Stavudine (d4T)

Sponsor: Merck Sharp & Dohme LLC

Conditions HIV Infections

Interventions Indinavir sulfate Stavudine

Updated 7 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002354, this NA trial focuses on HIV Infections and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed NA
Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Jun 2022 [monthly]

Completed NA

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Whitehouse Station, United States